
• Reported GAAP EPS of $0.69 up 35.29% YoY • Reported revenue of $381.88M up 7.46% YoY • Merit anticipates Total Revenue for the year ending December 31, 2026, to be $1.612-$1.634 billion, representing a 6%-8% year-over-year change, and Non-GAAP Earnings Per Share to be $4.01-$4.15, a 5%-8% change.
Bullish
Merit exceeded Q1 expectations with 7% revenue growth and 39% GAAP EPS increase. The company expanded its oncology portfolio via acquisition and improved non-GAAP operating margin to 19.7%.
Bearish
Merit faces risks from trade policies and challenges integrating acquisitions, which could impact anticipated benefits. Additionally, non-GAAP gross margin slightly compressed, with expected headwinds from tariffs.